Brickell Biotech Stock Cash Flow From Operations
| BBIDelisted Stock | USD 1.79 0.34 23.45% |
Brickell Biotech fundamentals help investors to digest information that contributes to Brickell Biotech's financial success or failures. It also enables traders to predict the movement of Brickell Stock. The fundamental analysis module provides a way to measure Brickell Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Brickell Biotech stock.
Brickell |
Brickell Biotech Company Cash Flow From Operations Analysis
Brickell Biotech's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Brickell Biotech Cash Flow From Operations | (36.15 M) |
Most of Brickell Biotech's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Brickell Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
CompetitionIn accordance with the recently published financial statements, Brickell Biotech has (36.15 Million) in Cash Flow From Operations. This is 106.86% lower than that of the Biotechnology sector and 157.81% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 103.72% higher than that of the company.
Brickell Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Brickell Biotech's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Brickell Biotech could also be used in its relative valuation, which is a method of valuing Brickell Biotech by comparing valuation metrics of similar companies.Brickell Biotech is currently under evaluation in cash flow from operations category among its peers.
Brickell Fundamentals
| Return On Equity | -1.57 | |||
| Return On Asset | -0.8 | |||
| Operating Margin | (6.58) % | |||
| Current Valuation | (8.35 M) | |||
| Shares Outstanding | 2.87 M | |||
| Shares Owned By Insiders | 1.20 % | |||
| Shares Owned By Institutions | 13.07 % | |||
| Number Of Shares Shorted | 189.59 K | |||
| Price To Earning | (35.16) X | |||
| Price To Book | 0.41 X | |||
| Price To Sales | 1.45 X | |||
| Revenue | 404 K | |||
| Gross Profit | (27.83 M) | |||
| EBITDA | (39.38 M) | |||
| Net Income | (39.47 M) | |||
| Cash And Equivalents | 17.29 M | |||
| Cash Per Share | 6.52 X | |||
| Total Debt | 69 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 4.36 X | |||
| Book Value Per Share | 5.81 X | |||
| Cash Flow From Operations | (36.15 M) | |||
| Short Ratio | 0.62 X | |||
| Earnings Per Share | (0.42) X | |||
| Target Price | 17.83 | |||
| Number Of Employees | 16 | |||
| Beta | 0.0796 | |||
| Market Capitalization | 6.75 M | |||
| Total Asset | 29.72 M | |||
| Retained Earnings | (145.37 M) | |||
| Working Capital | 24.79 M | |||
| Current Asset | 52.66 M | |||
| Current Liabilities | 5.61 M | |||
| Net Asset | 29.72 M |
About Brickell Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Brickell Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brickell Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brickell Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Brickell Stock
If you are still planning to invest in Brickell Biotech check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Brickell Biotech's history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |